Loading stock data…
$0.95+0.00 (+0.44%)
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
Immuron Limited in the Healthcare sector is trading at $0.95 with a market capitalization of $9M. Wall Street consensus targets $3.93 (1 analysts), implying a +312.3% move over the next 12 months. The stock is currently near its 52-week low of $0.68, remaining 6.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immu...